Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.

Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ.

Oncogene. 2008 May 1;27(20):2851-7. Epub 2007 Nov 19.

PMID:
18026137
2.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC.

Nat Med. 2005 Mar;11(3):312-9. Epub 2005 Feb 13.

PMID:
15711557
3.

Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

Gaspari P, Banerjee T, Malachowski WP, Muller AJ, Prendergast GC, DuHadaway J, Bennett S, Donovan AM.

J Med Chem. 2006 Jan 26;49(2):684-92.

4.

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.

Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F.

Clin Cancer Res. 2008 Nov 15;14(22):7251-9. doi: 10.1158/1078-0432.CCR-08-0991.

5.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

6.

Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.

Liu X, Newton RC, Friedman SM, Scherle PA.

Curr Cancer Drug Targets. 2009 Dec;9(8):938-52. Review.

PMID:
20025603
7.

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

Muller AJ, Malachowski WP, Prendergast GC.

Expert Opin Ther Targets. 2005 Aug;9(4):831-49. Review.

PMID:
16083346
8.

Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage.

Mehta RG, Liu J, Constantinou A, Thomas CF, Hawthorne M, You M, Gerhüser C, Pezzuto JM, Moon RC, Moriarty RM.

Carcinogenesis. 1995 Feb;16(2):399-404.

PMID:
7859373
9.

A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.

Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD.

Clin Cancer Res. 2009 Jan 15;15(2):641-9. doi: 10.1158/1078-0432.CCR-08-1988.

10.

Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.

Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC.

Cancer Res. 2010 Mar 1;70(5):1845-53. doi: 10.1158/0008-5472.CAN-09-3613. Epub 2010 Feb 16. Erratum in: Cancer Res. 2010 Apr 15;70(8):3414.

11.

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.

Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F.

Gynecol Oncol. 2009 Nov;115(2):185-92. doi: 10.1016/j.ygyno.2009.07.015. Epub 2009 Aug 8.

PMID:
19665763
12.

The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.

Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH.

J Immunother. 2009 Jan;32(1):22-8. doi: 10.1097/CJI.0b013e31818ac2f7.

PMID:
19307990
13.

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

Dolušić E, Larrieu P, Blanc S, Sapunaric F, Norberg B, Moineaux L, Colette D, Stroobant V, Pilotte L, Colau D, Ferain T, Fraser G, Galleni M, Frère JM, Masereel B, Van den Eynde B, Wouters J, Frédérick R.

Bioorg Med Chem. 2011 Feb 15;19(4):1550-61. doi: 10.1016/j.bmc.2010.12.032. Epub 2010 Dec 16. Erratum in: Bioorg Med Chem. 2011 May 1;19(9):3029. Galeni, Moreno [corrected to Galleni, Moreno].

PMID:
21269836
14.

Marrying immunotherapy with chemotherapy: why say IDO?

Muller AJ, Prendergast GC.

Cancer Res. 2005 Sep 15;65(18):8065-8. Review.

15.

Structure-activity relationships of brassinin in preventing the development of carcinogen-induced mammary lesions in organ culture.

Mehta RG, Liu J, Constantinou A, Hawthorne M, Pezzuto JM, Moon RC, Moriarty RM.

Anticancer Res. 1994 May-Jun;14(3A):1209-13.

PMID:
8074474
16.

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.

Yue EW, Douty B, Wayland B, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Liu C, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Metcalf B, Scherle PA, Combs AP.

J Med Chem. 2009 Dec 10;52(23):7364-7. doi: 10.1021/jm900518f.

PMID:
19507862
17.

Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression.

Liu H, Liu L, Liu K, Bizargity P, Hancock WW, Visner GA.

J Immunol. 2009 Jul 15;183(2):1022-31. doi: 10.4049/jimmunol.0900408. Epub 2009 Jun 29.

18.

Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock.

Jung ID, Lee MG, Chang JH, Lee JS, Jeong YI, Lee CM, Park WS, Han J, Seo SK, Lee SY, Park YM.

J Immunol. 2009 Mar 1;182(5):3146-54. doi: 10.4049/jimmunol.0803104.

19.

A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.

Yang HJ, Yen MC, Lin CC, Lin CM, Chen YL, Weng TY, Huang TT, Wu CL, Lai MD.

Exp Biol Med (Maywood). 2010 Jul;235(7):869-76. doi: 10.1258/ebm.2010.010001.

PMID:
20558841
20.

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Muller AJ, Prendergast GC.

Curr Cancer Drug Targets. 2007 Feb;7(1):31-40. Review.

PMID:
17305476

Supplemental Content

Support Center